Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6217739 | 0.92 | BAZ2B (0.51) | CCR1MEN1GAAMAPTALOX15 | |
| SCHEMBL6215226 | 0.91 | ALDH1A1 (0.49) | CCR1MEN1GAAMAPTALOX15 | |
| SCHEMBL6217113 | 0.91 | MEN1 (0.58) | CCR1MEN1GAAMAPTALOX15 | |
| SCHEMBL6212588 | 0.89 | HDAC1 (0.49) | CCR1MEN1GAAMAPTALOX15 | |
| SCHEMBL6211345 | 0.89 | CCR1 (0.52) | CCR1MEN1GAAMAPTALOX15 | |
| SCHEMBL6218306 | 0.87 | CCR1 (0.52) | CCR1MEN1GAAMAPTALOX15 | |
| SCHEMBL6218103 | 0.85 | NPSR1 (0.49) | CCR1MEN1GAAMAPTALOX15 | |
| SCHEMBL6213814 | 0.84 | CCR1 (0.58) | CCR1MEN1GAAMAPTALOX15 | |
| SCHEMBL6215974 | 0.83 | HDAC1 (0.51) | CCR1MEN1MAPTALOX15KMT2A | |
| SCHEMBL6215795 | 0.82 | MEN1 (0.58) | CCR1MEN1GAAMAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927222-B2 | 1,3,4,5-tetrahydro-pyrido(4,3-b)indole-2-yl derivative useful for treating rheumatoid arthritis, chronic obstructive pulmonary disease, asthma and multple sclerosis | ASTRAZENECA AB (SE) | 2005-08-09 | — | — | US | claimed |
| US-20030144267-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | claimed |
| EP-1263760-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | claimed |
| WO-2001062757-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | claimed |
| US-6951874-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-10-04 | — | — | US | disclosed |
| US-6943188-B2 | Hydroxyalkyl compounds | ASTRAZENECA AB (SE) | 2005-09-13 | — | — | US | disclosed |
| US-6927222-B2 | 1,3,4,5-tetrahydro-pyrido(4,3-b)indole-2-yl derivative useful for treating rheumatoid arthritis, chronic obstructive pulmonary disease, asthma and multple sclerosis | ASTRAZENECA AB (SE) | 2005-08-09 | — | — | US | disclosed |
| EP-1263724-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | EP | disclosed |
| US-20030158225-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | US | disclosed |
| US-20030149047-A1 | Novel compounds | ASTRAZENCA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| US-20030144267-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
| EP-1263725-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1263724-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001062729-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062728-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158225-A1 | Novel compounds | UGT2B7, RPS4Y1, RPS4X | CCR1 867/4885MEN1 1294/4885GAA 579/4885 |
| US-20030149047-A1 | Novel compounds | RPS4Y1, RPS4X, RPS6 | CCR1 747/4885MEN1 1120/4885GAA 584/4885 |
| US-20030144267-A1 | Novel compounds | RPS4X, RPS4Y1, UGT2B7 | CCR1 1236/4885MEN1 1455/4885GAA 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.